Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Bosch

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Communications Medicine|February 16, 2026
Homologous recombination deficiency in primary ER-positive and HER2-negative breast cancerHelen R Davies, Daniella Black, Anders Kvist, et al.
Breast Cancer Research and Treatment|January 4, 2024
The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trialYajing Zhu, Ioannis Zerdes, Alexios Matikas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 30, 2022
Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 TrialAlexios Matikas, Hemming Johansson, Per Grybäck, et al.
Nature Medicine|October 2, 2019
Whole-genome sequencing of triple-negative breast cancers in a population-based clinical studyJohan Staaf, Dominik Glodzik, Ana Bosch, et al.
Molecular Cell|March 4, 2021
Oncogenic translation directs spliceosome dynamics revealing an integral role for SF3A3 in breast cancerMaciej Cieśla, Phuong Cao Thi Ngoc, Eugenia Cordero, et al.
Science Translational Medicine|August 2, 2013
mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancerMoshe Elkabets, Sadhna Vora, Dejan Juric, et al.
Cancer Letters|November 19, 2025
Fibrillarin-dependent 2'-O-methylation modulates RPS28 ribosome incorporation and oncogenic translationPaula Groza, Kanchan Kumari, Margalida Esteva-Socias, et al.
Nature Communications|July 29, 2020
Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancersDominik Glodzik, Ana Bosch, Johan Hartman, et al.
Cell Reports|June 20, 2019
The X-Linked DDX3X RNA Helicase Dictates Translation Reprogramming and Metastasis in MelanomaBengt Phung, Maciej Cieśla, Adriana Sanna, et al.
JAMA Oncology|June 24, 2021
Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical TrialThomas Hatschek, Theodoros Foukakis, Judith Bjöhle, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Communications Medicine|February 16, 2026
Homologous recombination deficiency in primary ER-positive and HER2-negative breast cancerHelen R Davies, Daniella Black, Anders Kvist, et al.
Breast Cancer Research and Treatment|January 4, 2024
The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trialYajing Zhu, Ioannis Zerdes, Alexios Matikas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 30, 2022
Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 TrialAlexios Matikas, Hemming Johansson, Per Grybäck, et al.
Nature Medicine|October 2, 2019
Whole-genome sequencing of triple-negative breast cancers in a population-based clinical studyJohan Staaf, Dominik Glodzik, Ana Bosch, et al.
Molecular Cell|March 4, 2021
Oncogenic translation directs spliceosome dynamics revealing an integral role for SF3A3 in breast cancerMaciej Cieśla, Phuong Cao Thi Ngoc, Eugenia Cordero, et al.
Science Translational Medicine|August 2, 2013
mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancerMoshe Elkabets, Sadhna Vora, Dejan Juric, et al.
Cancer Letters|November 19, 2025
Fibrillarin-dependent 2'-O-methylation modulates RPS28 ribosome incorporation and oncogenic translationPaula Groza, Kanchan Kumari, Margalida Esteva-Socias, et al.
Nature Communications|July 29, 2020
Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancersDominik Glodzik, Ana Bosch, Johan Hartman, et al.
Cell Reports|June 20, 2019
The X-Linked DDX3X RNA Helicase Dictates Translation Reprogramming and Metastasis in MelanomaBengt Phung, Maciej Cieśla, Adriana Sanna, et al.
JAMA Oncology|June 24, 2021
Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical TrialThomas Hatschek, Theodoros Foukakis, Judith Bjöhle, et al.
Pageof 5